Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2005

Cramer SF. I enjoyed the article about reserve cells. Hum Pathol. 2005;36(8):932-3; author reply 934-5.

Kim HJ, Schleiffarth JR, Jessurun J, Sumanas S, Petryk A, Lin S, et al. Wnt5 signaling in vertebrate pancreas development. BMC Biol. 2005;3:23.

Mussak EN, Tu JJ, Voigt EP. Malignant solitary fibrous tumor of the hypopharynx with dysphagia. Otolaryngol Head Neck Surg. 2005;133(5):805-7.

Da Wu K-, Cho YS, Katz J, Ponomarev V, Chen-Kiang S, Danishefsky SJ, et al. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci U S A. 2005;102(30):10640-5.

Simmons WJ, Koneru M, Mohindru M, Thomas R, Cutro S, Singh P, et al. Tim-3+ T-bet+ tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasms. J Immunol. 2005;174(3):1405-15.

Fan G, Molstad M, Braziel RM, Standley M, Huang J, Rodgers W, et al. Proteomic profiling of mature CD10+ B-cell lymphomas. Am J Clin Pathol. 2005;124(6):920-9.

Lesinski GB, Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother. 2005;54(9):815-25.

Ying H, Chang DL, Zheng H, McKeon F, Xiao Z-. DNA-binding and transactivation activities are essential for TAp63 protein degradation. Mol Cell Biol. 2005;25(14):6154-64.

Breza TS, Magro CM. CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype. J Cutan Pathol. 2005;32(10):685-9.

Aslan DL, H Gulbahce E, Pambuccian SE, J Manivel C, Jessurun J. Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact. Am J Clin Pathol. 2005;123(6):874-8.